Webinar Announcement: Improving lentiviral vector yield with 2G UNic technology

Join NecstGen and ProteoNic for our webinar “Improving lentiviral vector yield with 2G UNic technology”, presented by Maurice van der Heijden (Director of R&D, ProteoNic) and Diederik Lokhorst (Viral Vector Scientist, NecstGen).

Discover more about ProteoNic’s 2G UNic™ technology and how NecstGen has been applying the technology for Lentiviral (LV) production. Learn from our experts while they discuss several aspects of LV production, a major cost driver in both gene therapies and Ex vivo gene therapies, and how both companies are working together to improve it.

Register now to secure your spot and stay tuned for more updates!

Register here

The First Stages of CAR T Cell Therapy Development

The First Stages of CAR T Cell Therapy Development

Chimeric Antigen Receptor (CAR) T cell therapy represents a transformative approach in medicine, particularly in oncology. This method offers personalised treatment by harnessing a patient's immune system to target and eliminate (cancer) cells. These novel therapies...

Webinar LV Process for CAR T

Webinar LV Process for CAR T

Shifting from traditional, ad hoc methodologies to a structured, data-based development approach to create a scalable, GMP-ready process.

NecstGen Services

Cell Therapy Development & Manufacturing

Viral Vector Development & Manufacturing

Cleanroom Rental

About Us

NecstGen is a non-profit CDMO and Centre of Excellence for Cell and Gene Therapy located in a purpose-built GMP facility in Leiden, The Netherlands. Dedicated to the field of Cell and Gene Therapies, we provide expertise and capacity.

NecstGen

Team

Partners

History

Facility

Ecosystem